Clozapine's functional mesolimbic selectivity is not duplicated by the addition of anticholinergic action to haloperidol: a brain stimulation study in the rat

Eliot L. Gardner, Leslie Stern Walker, William Paredes

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

This study examined whether the anticholinergic potency of the clinically superior antipsychotic drug clozapine contributes to clozapine's anatomically-selective functional inhibition of the mesolimbic dopamine (DA) system, using an electrical brain-stimulation reward (BSR) paradigm in rats that has been previously shown to be highly sensitive to clozapine's mesolimbic functional selectivity. Rats were chronically administered saline, clozapine, haloperidol, or haloperidol plus the anticholinergic compound trihexyphenidyl, and threshold sensitivity of the mesolimbic and nigrostriatal DA systems was assessed using the BSR paradigm, to infer degree of functional DA blockade produced by the chronic drug regimens. Chronic saline produced no change in either DA system. Congruent with previous findings, chronic clozapine powerfully inhibited the mesolimbic DA system but spared the nigrostriatal DA system. Also congruent with previous findings, chronic haloperidol powerfully inhibited both DA systems. Compared to chronic haloperidol alone, chronic haloperidol plus chronic trihexyphenidyl exerted diminished anti-DA action in both the mesolimbic and nigrostriatal DA systems. These results suggest that clozapine's anticholinergic potency is not an adequate explanation for its functional mesolimbic selectivity.

Original languageEnglish (US)
Pages (from-to)119-124
Number of pages6
JournalPsychopharmacology
Volume110
Issue number1-2
DOIs
StatePublished - Jan 1993

Fingerprint

Clozapine
Cholinergic Antagonists
Haloperidol
Dopamine
Brain
Trihexyphenidyl
Reward
Deep Brain Stimulation
Antipsychotic Agents

Keywords

  • Acetylcholine
  • Antipsychotic
  • Atypical
  • Brain stimulation reward
  • Clozapine
  • Dopamine
  • Haloperidol
  • ICSS
  • Mesolimbic
  • Neuroleptic
  • Nigrostriatal
  • Psychosis
  • Schizophrenia
  • Self-stimulation
  • Substantia nigra
  • Trihexyphenidyl
  • Ventral tegmental area

ASJC Scopus subject areas

  • Pharmacology

Cite this

Clozapine's functional mesolimbic selectivity is not duplicated by the addition of anticholinergic action to haloperidol : a brain stimulation study in the rat. / Gardner, Eliot L.; Walker, Leslie Stern; Paredes, William.

In: Psychopharmacology, Vol. 110, No. 1-2, 01.1993, p. 119-124.

Research output: Contribution to journalArticle

@article{9775f30e9728486992d4b5e6e861e9b7,
title = "Clozapine's functional mesolimbic selectivity is not duplicated by the addition of anticholinergic action to haloperidol: a brain stimulation study in the rat",
abstract = "This study examined whether the anticholinergic potency of the clinically superior antipsychotic drug clozapine contributes to clozapine's anatomically-selective functional inhibition of the mesolimbic dopamine (DA) system, using an electrical brain-stimulation reward (BSR) paradigm in rats that has been previously shown to be highly sensitive to clozapine's mesolimbic functional selectivity. Rats were chronically administered saline, clozapine, haloperidol, or haloperidol plus the anticholinergic compound trihexyphenidyl, and threshold sensitivity of the mesolimbic and nigrostriatal DA systems was assessed using the BSR paradigm, to infer degree of functional DA blockade produced by the chronic drug regimens. Chronic saline produced no change in either DA system. Congruent with previous findings, chronic clozapine powerfully inhibited the mesolimbic DA system but spared the nigrostriatal DA system. Also congruent with previous findings, chronic haloperidol powerfully inhibited both DA systems. Compared to chronic haloperidol alone, chronic haloperidol plus chronic trihexyphenidyl exerted diminished anti-DA action in both the mesolimbic and nigrostriatal DA systems. These results suggest that clozapine's anticholinergic potency is not an adequate explanation for its functional mesolimbic selectivity.",
keywords = "Acetylcholine, Antipsychotic, Atypical, Brain stimulation reward, Clozapine, Dopamine, Haloperidol, ICSS, Mesolimbic, Neuroleptic, Nigrostriatal, Psychosis, Schizophrenia, Self-stimulation, Substantia nigra, Trihexyphenidyl, Ventral tegmental area",
author = "Gardner, {Eliot L.} and Walker, {Leslie Stern} and William Paredes",
year = "1993",
month = "1",
doi = "10.1007/BF02246960",
language = "English (US)",
volume = "110",
pages = "119--124",
journal = "Psychopharmacology",
issn = "0033-3158",
publisher = "Springer Verlag",
number = "1-2",

}

TY - JOUR

T1 - Clozapine's functional mesolimbic selectivity is not duplicated by the addition of anticholinergic action to haloperidol

T2 - a brain stimulation study in the rat

AU - Gardner, Eliot L.

AU - Walker, Leslie Stern

AU - Paredes, William

PY - 1993/1

Y1 - 1993/1

N2 - This study examined whether the anticholinergic potency of the clinically superior antipsychotic drug clozapine contributes to clozapine's anatomically-selective functional inhibition of the mesolimbic dopamine (DA) system, using an electrical brain-stimulation reward (BSR) paradigm in rats that has been previously shown to be highly sensitive to clozapine's mesolimbic functional selectivity. Rats were chronically administered saline, clozapine, haloperidol, or haloperidol plus the anticholinergic compound trihexyphenidyl, and threshold sensitivity of the mesolimbic and nigrostriatal DA systems was assessed using the BSR paradigm, to infer degree of functional DA blockade produced by the chronic drug regimens. Chronic saline produced no change in either DA system. Congruent with previous findings, chronic clozapine powerfully inhibited the mesolimbic DA system but spared the nigrostriatal DA system. Also congruent with previous findings, chronic haloperidol powerfully inhibited both DA systems. Compared to chronic haloperidol alone, chronic haloperidol plus chronic trihexyphenidyl exerted diminished anti-DA action in both the mesolimbic and nigrostriatal DA systems. These results suggest that clozapine's anticholinergic potency is not an adequate explanation for its functional mesolimbic selectivity.

AB - This study examined whether the anticholinergic potency of the clinically superior antipsychotic drug clozapine contributes to clozapine's anatomically-selective functional inhibition of the mesolimbic dopamine (DA) system, using an electrical brain-stimulation reward (BSR) paradigm in rats that has been previously shown to be highly sensitive to clozapine's mesolimbic functional selectivity. Rats were chronically administered saline, clozapine, haloperidol, or haloperidol plus the anticholinergic compound trihexyphenidyl, and threshold sensitivity of the mesolimbic and nigrostriatal DA systems was assessed using the BSR paradigm, to infer degree of functional DA blockade produced by the chronic drug regimens. Chronic saline produced no change in either DA system. Congruent with previous findings, chronic clozapine powerfully inhibited the mesolimbic DA system but spared the nigrostriatal DA system. Also congruent with previous findings, chronic haloperidol powerfully inhibited both DA systems. Compared to chronic haloperidol alone, chronic haloperidol plus chronic trihexyphenidyl exerted diminished anti-DA action in both the mesolimbic and nigrostriatal DA systems. These results suggest that clozapine's anticholinergic potency is not an adequate explanation for its functional mesolimbic selectivity.

KW - Acetylcholine

KW - Antipsychotic

KW - Atypical

KW - Brain stimulation reward

KW - Clozapine

KW - Dopamine

KW - Haloperidol

KW - ICSS

KW - Mesolimbic

KW - Neuroleptic

KW - Nigrostriatal

KW - Psychosis

KW - Schizophrenia

KW - Self-stimulation

KW - Substantia nigra

KW - Trihexyphenidyl

KW - Ventral tegmental area

UR - http://www.scopus.com/inward/record.url?scp=0027439495&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027439495&partnerID=8YFLogxK

U2 - 10.1007/BF02246960

DO - 10.1007/BF02246960

M3 - Article

C2 - 7870870

AN - SCOPUS:0027439495

VL - 110

SP - 119

EP - 124

JO - Psychopharmacology

JF - Psychopharmacology

SN - 0033-3158

IS - 1-2

ER -